Evolving Concepts in Anterior Segment Outcomes: Tackling Ocu -

Name: Evolving Concepts in Anterior Segment Outcomes: Tackling Ocular Surface Disease Podcast
Uploaded: 2020-06-22T08:00:00+00:00
Duration: 16 min 58 s
Description: In this audio interview, Douglas K. Devries, OD, discusses the negative impact of undiagnosed and untreated ocular surface disease. He give pearls for coma

Media formats available:

Details

Presenters

Overview
In this audio interview, Douglas K. Devries, OD, discusses the negative impact of undiagnosed and untreated ocular surface disease. He give pearls for comanaging cataract surgery patients, screening for meibomian gland dysfunction, and approaching OSD management in patients with comorbid conditions.
Supported by unrestricted educational grants from Alcon, Carl Zeiss Meditec, Inc., Glaukos, and Johnson & Johnson Vision
Learning Objectives
- Identify methods to improve surgical, and ocular surface and corneal disease outcomes through comanagement of cataract, refractive, and corneal patients
- Describe the impact that OSD has on contact lens wear and drop out as well as overall cataract and refractive surgery outcomes
- Compare and contrast traditional and new and emerging diagnostic tests in classifying ocular surface disease severity and differentiating MGD
- Increase confidence in making therapeutic decisions for OSD patients based on disease classification, including acute exacerbations of dry eye disease, chronic dry eye, and MGD
- Explore approaches to ocular surface toxicity when OSD patients are treated for comorbid conditions
Accreditation
This podcast has no credit associated with it.
Faculty and Disclosures
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
DISCLOSURE POLICY It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity. The following faculty have the following financial relationships with commercial interests: Douglas K. Devries, OD, and/or spouse had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant and Speakers Bureau: Alcon, Bausch+ Health, Bio Tissue, Dompe, Eyevance, Johnson & Johnson Vision, Lumeris, Novartis, OcuSoft, Sun, and TearLab, Share/Stockholder: RPS.
Erin K. Fletcher, MIT, director of compliance and education; Evolve; and Kate Fehlhaber, PhD, writer, have no financial relationships with commercial interests.
Disclaimer
OFF-LABEL STATEMENT This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. DISCLAIMER The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Alcon, Carl Zeiss Meditec, Inc., Glaukos, or Johnson & Johnson Vision.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 06/22/2020
Expiration Date: 06/30/2021